![Paul Reider](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Paul Reider
Keine laufenden Positionen mehr
Vermögen: 110 877 $ am 31.07.2026
Profil
Paul Reider is the founder of Raven Management, LLC, founded in 2013.
Former jobs include Member-Clinical Advisory Board at Tetraphase Pharmaceuticals, Inc., Vice President-Sales & Strategic Accounts at Puma Biotechnology, Inc. from 2019 to 2021, General Manager at Ipsen Biopharmaceuticals Canada, Inc. from 2015 to 2018, Principal at Amgen, Inc., and Chief Commercial Officer at Coherus Oncology, Inc. from 2022 to 2025.
Education includes undergraduate and MBA degrees from Bowling Green State University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
COHERUS ONCOLOGY, INC. 0,05 % | 16.04.2026 | 78.636 ( 0,05 % ) | 110 877 $ | 31.07.2026 |
Ehemalige bekannte Positionen von Paul Reider
| Unternehmen | Position | Ende |
|---|---|---|
| COHERUS ONCOLOGY, INC. | Corporate Officer/Principal | 30.04.2025 |
| PUMA BIOTECHNOLOGY, INC. | Vertrieb & Marketing | 01.01.2021 |
Ipsen Biopharmaceuticals Canada, Inc.
 Ipsen Biopharmaceuticals Canada, Inc. Medical DistributorsDistribution Services Part of Ipsen SA, Ipsen Biopharmaceuticals Canada, Inc. is a Canadian company that provides information and secure access related to Dysport Therapeutic, a registered trademark product. The company is based in ON. The company's website offers dedicated portals for healthcare professionals and patients, with healthcare professional login secured via IQVIA OneKey web authentication and patient access using an 8-digit drug identification number from their prescription. The company supports Canadian users with reliable information and secure access to Dysport Therapeutic resources. | Corporate Officer/Principal | 01.01.2018 |
| TETRAPHASE PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Ausbildung von Paul Reider
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
41
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Amgen, Inc.
 Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Tetraphase Pharmaceuticals, Inc.
 Tetraphase Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel antibiotics | Health Technology |
Bowling Green State University
 Bowling Green State University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Puma Biotechnology, Inc.
 Puma Biotechnology, Inc. Pharmaceuticals: MajorHealth Technology Operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer | Health Technology |
Coherus BioSciences, Inc.
 Coherus BioSciences, Inc. Pharmaceuticals: MajorHealth Technology Operates as a commercial-stage biopharmaceutical company that engages in research, development and commercialization of immunotherapies to treat cancer | Health Technology |
Ipsen Biopharmaceuticals Canada, Inc.
Ipsen Biopharmaceuticals Canada, Inc. Medical DistributorsDistribution Services Part of Ipsen SA, Ipsen Biopharmaceuticals Canada, Inc. is a Canadian company that provides information and secure access related to Dysport Therapeutic, a registered trademark product. The company is based in ON. The company's website offers dedicated portals for healthcare professionals and patients, with healthcare professional login secured via IQVIA OneKey web authentication and patient access using an 8-digit drug identification number from their prescription. The company supports Canadian users with reliable information and secure access to Dysport Therapeutic resources. | Distribution Services |
